Analysts think CELC stock price could increase by 54%
Aug 02, 2024, 6:25 AM
-10.74%
What does CELC do
Celcuity, Inc., a cellular analysis company based in Minneapolis, went public in 2017 and employs 45 people. Its main product, gedatolisib, targets specific cancer pathways and is in trials for treating advanced breast cancer.
8 analysts think CELC stock price will increase by 54.11%. The current median analyst target is $27.54 compared to a current stock price of $17.87. The lowest analysts target is $23.23 and the highest analyst target is $42.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.